The medical testing giant reported consolidated revenue of ¥114.48 billion for the period, marking a steady rise from the ¥108.58 billion recorded in the previous fiscal year. This growth was mirrored in the company’s core profitability, with operating profit climbing to ¥9.20 billion, up from ¥8.14 billion a year earlier.
Growth Across Key Metrics
The company’s pretax profit reached ¥9.63 billion, a significant improvement over the ¥8.44 billion seen in the same nine-month window last year. According to the financial statement, these results were calculated based on Japanese accounting standards and reflect a period of sustained operational momentum.

Comments (0)
No comments yet. Be the first!